SGLT2 inhibitors and MR antagonists both cause short-term increases in natriuresis and diuresis; however, these mechanisms may not represent the primary actions responsible for long-term cardioprotection in chronic HF patients. The gene discussed is NR3C2; the disease is hydrops fetalis.